Enliven Therapeutics, Inc. Major Shareholders & Ownership History
Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
---|---|---|---|---|---|
ORBIMED ADVISORS LLC | 05/15/2025 | 7.96 M | $156.64 M | 0.00% | 15.96% |
FMR LLC | 05/12/2025 | 6.61 M | $130.08 M | 1.75% | 13.21% |
COMMODORE CAPITAL LP | 05/15/2025 | 4.68 M | $92.00 M | 11.18% | 9.38% |
VR ADVISER, LLC | 05/15/2025 | 4.03 M | $79.24 M | 0.00% | 8.08% |
FAIRMOUNT FUNDS MANAGEMENT LLC | 05/15/2025 | 3.20 M | $63.03 B | 0.00% | 6.40% |
BLACKROCK, INC. | 05/02/2025 | 3.00 M | $59.00 M | 1.11% | 5.99% |
POLAR CAPITAL HOLDINGS PLC | 05/15/2025 | 2.37 M | $46.55 M | -1.02% | 4.73% |
VANGUARD GROUP INC | 05/09/2025 | 1.97 M | $38.81 M | -0.17% | 3.94% |
JANUS HENDERSON GROUP PLC | 05/15/2025 | 1.57 M | $33.05 M | 17.92% | 3.14% |
5AM VENTURE MANAGEMENT, LLC | 05/15/2025 | 1.32 M | $26.03 B | -18.85% | 2.64% |
CITADEL ADVISORS LLC | 05/15/2025 | 1.12 M | $22.10 M | -35.40% | 2.24% |
PICTET ASSET MANAGEMENT HOLDING SA | 05/05/2025 | 967.50 K | $19.04 M | -0.49% | 1.93% |
RA CAPITAL MANAGEMENT, L.P. | 05/15/2025 | 848.99 K | $16.71 M | 0.00% | 1.70% |
GEODE CAPITAL MANAGEMENT, LLC | 05/13/2025 | 819.17 K | $16.12 M | 7.40% | 1.64% |
WOODLINE PARTNERS LP | 05/15/2025 | 805.16 K | $15.85 M | -0.09% | 1.61% |
STATE STREET CORP | 05/15/2025 | 780.90 K | $15.37 M | -2.61% | 1.56% |
BLACKSTONE INC. | 05/15/2025 | 762.31 K | $15.00 M | 104.20% | 1.52% |
05/15/2025 | 671.36 K | $13.21 B | 0.00% | 1.34% | |
FIRST TURN MANAGEMENT, LLC | 05/15/2025 | 535.09 K | $10.53 M | 0.00% | 1.07% |
ROCK SPRINGS CAPITAL MANAGEMENT LP | 05/15/2025 | 465.87 K | $9.17 B | 8.70% | 0.93% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 05/15/2025 | 450.00 K | $8.86 M | -30.77% | 0.90% |
NORTHERN TRUST CORP | 05/13/2025 | 338.65 K | $6.66 M | 2.16% | 0.68% |
IKARIAN CAPITAL, LLC | 05/15/2025 | 289.54 K | $5.70 M | -26.61% | 0.58% |
ACUTA CAPITAL PARTNERS, LLC | 05/15/2025 | 265.27 K | $5.22 M | -0.79% | 0.53% |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 05/09/2025 | 259.54 K | $5.11 M | -0.90% | 0.52% |
PATIENT SQUARE CAPITAL LP | 05/14/2025 | 253.84 K | $5.00 M | 13.30% | 0.51% |
CORMORANT ASSET MANAGEMENT, LP | 05/15/2025 | 250.00 K | $4.92 M | 0.00% | 0.50% |
LOGOS GLOBAL MANAGEMENT LP | 05/15/2025 | 240.00 K | $4.72 B | 71.43% | 0.48% |
GOLDMAN SACHS GROUP INC | 05/16/2025 | 211.75 K | $4.17 M | 61.34% | 0.42% |
LORD, ABBETT & CO. LLC | 05/13/2025 | 197.28 K | $3.88 M | -48.92% | 0.39% |
ALLY BRIDGE GROUP (NY) LLC | 05/15/2025 | 169.77 K | $3.34 M | 19.80% | 0.34% |
POINT72 ASSET MANAGEMENT, L.P. | 05/15/2025 | 139.92 K | $2.75 M | 100.00% | 0.28% |
MILLENNIUM MANAGEMENT LLC | 05/15/2025 | 132.89 K | $2.62 M | 161.57% | 0.27% |
STEMPOINT CAPITAL LP | 05/15/2025 | 120.43 K | $2.37 M | 24.52% | 0.24% |
BAKER BROS. ADVISORS LP | 05/15/2025 | 114.83 K | $2.26 M | 0.00% | 0.23% |
HIGHVISTA STRATEGIES LLC | 05/15/2025 | 112.46 K | $2.21 M | 0.00% | 0.22% |
SPHERA FUNDS MANAGEMENT LTD. | 05/15/2025 | 111.74 K | $2.20 M | 100.00% | 0.22% |
RUSSELL INVESTMENTS GROUP, LTD. | 05/13/2025 | 105.54 K | $2.08 M | 148,550.70% | 0.21% |
05/12/2025 | 104.10 K | $2.05 M | 100.00% | 0.21% | |
BANK OF NEW YORK MELLON CORP | 04/29/2025 | 93.57 K | $1.84 M | 4.46% | 0.19% |
WELLINGTON MANAGEMENT GROUP LLP | 05/13/2025 | 84.70 K | $1.67 M | 4.68% | 0.17% |
MORGAN STANLEY | 05/15/2025 | 81.32 K | $1.60 M | -26.48% | 0.16% |
BOOTHBAY FUND MANAGEMENT, LLC | 05/15/2025 | 76.98 K | $1.51 M | -26.61% | 0.15% |
FEDERATED HERMES, INC. | 05/08/2025 | 69.05 K | $1.36 M | -41.26% | 0.14% |
RHUMBLINE ADVISERS | 05/29/2025 | 52.50 K | $1.03 M | 4.93% | 0.10% |
BARCLAYS PLC | 05/15/2025 | 50.36 K | $991.00 K | -22.00% | 0.10% |
STATE OF WISCONSIN INVESTMENT BOARD | 05/15/2025 | 45.76 K | $900.48 K | 70.51% | 0.09% |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 05/14/2025 | 44.92 K | $883.93 K | 189.21% | 0.09% |
SWISS NATIONAL BANK | 05/12/2025 | 41.87 K | $824.06 K | 0.00% | 0.08% |
ALLIANCEBERNSTEIN L.P. | 05/15/2025 | 36.84 K | $725.01 K | 0.00% | 0.07% |
Enliven Therapeutics, Inc. institutional Ownership - FAQ's
During the previous two years, 122 institutional investors and hedge funds held shares of Enliven Therapeutics, Inc.. The most heavily invested institutionals were:
ORBIMED ADVISORS LLC: 7.96 M
FMR LLC: 6.61 M
COMMODORE CAPITAL LP: 4.68 M
VR Adviser, LLC: 4.03 M
Fairmount Funds Management LLC: 3.2 M
BlackRock, Inc.: 3 M
99.67% of Enliven Therapeutics, Inc. stock is owned by institutional investors.
Institutional investors have bought a total of 52.45 M shares in the last 24 months. This purchase volume represents approximately $1.15 B in transactions.